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PathogenesisAbstract Propionibacterium acnes is an anaerobic, Gram-positive, opportunistic pathogen known
to be involved in a wide variety of diseases ranging from mild acne to prostate cancer. Bacterial
small non-coding RNAs are novel regulators of gene expression and are known to be involved
in, virulence, pathogenesis, stress tolerance and adaptation to environmental changes in bacteria.
The present study was undertaken keeping in view the lack of predicted sRNAs of P. acnes
KPA171202 in databases. This report represents the first attempt to identify sRNAs in P. acnes
KPA171202. A total of eight potential candidate sRNAs were predicted using SIPHT, one was
found to have a Rfam homolog and seven were novel. Out of these seven predicted sRNAs, five
were validated by reverse transcriptase-polymerase chain reaction (RT-PCR) and sequencing.
The expression of these sRNAs was quantified in different growth phases by qPCR (quantitative
PCR). They were found to be expressed in both exponential and stationary stages of growth but
with maximum expression in stationary phase which points to a regulatory role for them. Further
investigation of their targets and regulatory functions is in progress.
 2016 Production and hosting by Elsevier B.V. on behalf of Academy of Scientific Research &
Technology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Propionibacterium acnes is a Gram-positive, non-spore form-
ing, micro-aerophilic, pleomorphic rod shaped opportunistic
pathogen with an optimal growing temperature of 37 C. The
bacterium has been found to be involved in a wide array of dis-
eases ranging from acne [25] to prostate inflammation leading
to prostate cancer [1,7]. Other diseases in which the bacterium
was isolated from the site of inflammation include, rheumatoidarthritis, endophthalmitis, shunt-associated central nervous
system infections, endocarditis, sarcoidosis, osteomyelitis,
allergic alveolitis, pulmonary angitis, acne inversa and SAPHO
(synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome [5].
Colonization by P. acnes in the pilosebaceous follicle is a key
factor for inflammatory reaction in acne vulgaris [25]. Acne
can manifest as a mild comedonal form to chronic inflamma-
tory cystic acne on the face, chest, and back. The antibiotic
therapy involves the use of erythromycin, clindamycin and
tetracycline for weeks and months resulting in evolution of
resistant strains. It thus becomes necessary to look for alterna-
tive therapeutics which do not lend themselves to development
of resistance. The sequencing of P. acnes KPA171202 genome
170 P.P. Balgir et al.by Bruggemann and co-workers [6], leads to the annotation of
genes involved in pathogenesis and virulence [4]. It has also
brought up an opportunity to identify small regulatory RNAs
among the P. acnes genome sequences.
Small RNAs (sRNAs) are small regulatory RNAs, occur-
ring in prokaryotes; in addition to the already known messen-
ger (mRNA), transfer (tRNA) and ribosomal (rRNA). Their
sizes range from 30 to 600 nts approximately in length and
are usually not translated into proteins. These are encoded
by intergenic regions (IGRs) of bacterial chromosomes and
are transcribed from their own promoters. Their transcription
most often terminates at a strong Rho-independent termina-
tor. The sRNAs might be transcribed in cis i.e. encoded on
the strand opposite to the gene they regulate, or in trans i.e.
away from the target genes. The trans acting-sRNAs act by
partial or imperfect base pairing with the target transcripts
while the cis acting-sRNAs have a region of perfect comple-
mentarity with the target transcript. In some cases, the sRNAs
are expressed under highly specific growth conditions [10].
MicF was the first trans-encoded antisense RNA found in
the Escherichia coli genome [22,23]. It showed partial and
imperfect sequence complementarity to its target ompF
(encoding outer membrane protein F) mRNA near the start
codon, leading to strong translation inhibition. Classically,
sRNAs were defined as short non-coding transcripts that,
together with the RNA chaperone protein, Hfq, act in trans
to control the translation or stability of target mRNAs. This
definition was broadened by Liu and Camilli [16], as many
coding, cis-acting and Hfq-independent sRNAs were also rec-
ognized. RNAIII of Staphylococcus aureus is a cis-acting regu-
latory RNA that also encodes a virulence factor d-hemolysin
[3]. SymR of E. coli is an example of Hfq-independent,
cis-acting sRNA that represses the translation of symE which
encodes for a toxic protein [13].
Binding of sRNA with its target may lead to translational
activation or it may also lead to translational repression. These
have been involved in the regulation of metabolism, growth
processes, adaptation to stress, and pathogenesis of micro-
organisms [21]. Their regulatory nature also makes them attrac-
tive targets for developing nucleic acid based novel therapeutics.
There are many approaches to identify and characterize sRNA
molecules, their genes and targets in prokaryotes. These include
genome-wide searches based on the bio-computational predic-
tion of sRNA encoding genes. First evidence of sRNAs came
in 2001 when three different groups [2,29,34] at the same time
developed algorithms and identified 31 new sRNA in E. coli.
Later on genomes of several organisms were explored for the
presence of sRNA candidates. Some authors developed their
own in silico approaches for sRNA prediction [33,36], while
others used various web based tools singularly [28] or a combi-
nation of few tools [35]. Some researchers have used genome
tilling microarrays for finding new sRNA transcripts and inves-
tigating sRNA expression. However, the microarray results
need to be validated by northern blots or qPCR and analyzed
further by RACE (rapid amplification of cDNA ends); for
end-mapping to discriminate novel sRNA genes from leader
sequences of genes. Microarrays were used for sRNA identifica-
tion inCaulobacter crescentus by Landt and co-workers [15] and
could verify only 27 out of 300 predicted sRNAs. Various other
methods include cDNA library synthesis, next-generation
sequencing, northern blotting, RT-PCR analysis of predicted
genes and co-purification with proteins like hfq.Present study systematically identified sRNAs in the
P. acnes genome beginning with computational approach
based on gene localization, intergenic sequence conservation,
terminator and secondary structure prediction, followed by
validation of predicted sRNAs in experimental approach using
qPCR. The results indicate existence of seven and validation of
five hitherto unreported sRNAs in P. acnes which might
play a potential role in regulating gene expression and/or
pathogenesis.2. Materials and methods
2.1. Bacterial strains and culture conditions
P. acnes (strain KPA171202/DSM 16379) was procured form
DSMZ Germany (German Collection of Microorganisms
and cell cultures). The culture was maintained in Brain Heart
Infusion Broth at 37 C for 48–72 h in anaerobic jar containing
5% CO2 and on BHI plates supplemented with Vitamin K
(10 lg/ml) and Haemin (5 l/ml) at 37 C. The growth rate of
P. acnes in BHI media was monitored spectrophotometrically
by observing OD at 600 nm after every 3 h till 78 h. Growth
curve was plotted using optical density against time plot
(Fig. 1).
2.2. In silico prediction of candidate sRNA genes
Genome sequences of P. acnes KPA171202 were downloaded
from NCBI server for insilico prediction. Small RNA candi-
dates of P. acnes were predicted using the web interface SIPHT
(sRNA Identification Protocol using High-throughput Tech-
nologies) using default parameters [18]. SIPHT identifies
sRNA encoding genes based on intergenic conservation and
Rho-independent terminators. Each locus is annotated for
many features like sequence conservation in other closely
related species, promoter and transcription factor binding site,
conserved secondary structure etc that provide information for
its potential function. The performance and reliability of the
tool was assessed and compared with other algorithms also
[20].
2.3. Nomenclature of the sRNAs
Each candidate sRNAs detected by PCR and confirmed by
sequencing are indicated by initial ‘‘s” (in lowercase), followed
by genome identification as used in NCBI database (in upper-
case); ending with the number of candidate as predicted by
SIPHT. For example: ‘sPPAK1’ for sRNA of Propionibac-
terium acnes KPA171202 candidate 1.
2.4. Insilico validation of predicted sRNAs
The sequences were scanned for the presence of
Shine-Dalgarno (SD) sequence, start codons, stop codons
and rho independent terminators. ARNold was used for
rho-independent transcription terminator prediction [26].
Secondary structure predictions were carried out using
RNAfold program [12] with default parameters. The predicted
sRNAs were scanned in Rfam database to check for
novelty [11].
Table 1 Sequences of PCR primers used for amplifying sRNA genes.
Primer Nucleotide sequence PCR product length (bp)
sPPAK1 FWD-50 ATCCTCGCGTTCTTACCACC 30
REV-50 TTGTTGGGGTCTGGATCTGC 30
160
sPPAK2 FWD-50 TGCGGCCCAGTCACCAC 30
REV-50 GCCACGAATGAGCGAGTCAG 30
59
sPPAK4 FWD-50 CTTACGGCGGGTTCCATC 30
REV-50 CAGTGGCTGCTGTGTGTGAC 30
220
sPPAK5 FWD-50 GGCAAAGCCCCAAGGCAC 30
REV-50 CCTAGCCGCCAAAAGGTG 30
132
sPPAK7 FWD-50 GCTGTGGGCCCGACGC 30
REV-50 CGAAAAAGCAGAGGCTCTG 30
194
RecA FWD-50 GGCTCTCGAGATTGCTGACA 30
REV-50 GAATCACCCATCTCGCCCTC 30
114
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Small RNA fraction was extracted from 36 h culture using
RNAzol reagent (Sigma) according to the manufacturer’s
instructions incorporating minor modifications from small
RNA enrichment method of Lu and co-workers [19]. Total
small RNA fraction was first polyadenylated using Poly(A)
polymerase (New England Biolabs, USA) and then reverse
transcribed using oligo dT primer (Thermoscientific Fisher sci-
entific) and Revertaid Reverse Tansranscriptase (Thermoscien-
tific Fisher scientific) according to the manufacturer’s
protocol. The resulting cDNA was further used for gene speci-
fic polymerase chain reaction (PCR) using primers designed by
PrimerBLAST as listed in Table 1 and Taq DNA polymerase
(New England Biolabs, USA). Mastercycler (Eppendorf,
Hamburg, Germany) was used to perform gradient PCR, with
an initial denaturation of 5 min at 95 C, followed by 30 ampli-
fication cycles of 15 s at 95 C, 10 s at 56–64 C, and 15 s at
72 C, and final extension was done for 5 min at 72 C. The
PCR products were visualized by silver staining 15% Polyacry-
lamide gel after electrophoresis for 2 h at 100 V along with
pUC19/MspI digest DNA ruler (Merck). For sequencing, the
same products were separated on 3% agarose gel electrophore-
sis and gel slices were excised for purification using Gel extrac-
tion Kit (Merck) according to the manufacturer’s protocol.
The samples were sent for sequencing to Xcelris Labs Ltd.
2.6. Quantitative real-time PCR
qPCR was performed to check the cellular abundance of the
validated sRNA i.e. sPPAK1, sPPAK2, sPPAK4, sPPAK5
and sPPAK7, at different growth phases. P. acnes was grown
for 36 (Exponential) and 72 (Stationary) hrs OD600 respec-
tively. Cells were harvested and used for RNA isolation as
described earlier. The polyadenylated and reverse transcribed
cDNA aliquots of each sample in equal concentration were
used in qPCR reaction mixture containing 5 ll of KAPA
SYBR FAST qPCR Master Mix (Kapa Biosystems, Cape
Town, South Africa), 10 pM of each primer (forward and
reverse) and final volume was made up to 10 ll with nuclease
free water. RecA was used as internal control for normalization
of gene expression. PCR was run on Mastercycler
(Eppendorf, Hamburg, Germany) with initial denaturation of5 min at 95 C and a subsequent run of 30 cycles each compris-
ing 10 s at 95 C, 10 s at 63 C, and 15 s at 72 C, and final
extension was done for 5 min at 72 C. The samples were run
in triplicate. The 2DDCT method (relative quantitation) was
used in which CT value (threshold cycle) was normalized to
endogenous reference geneRecA (DCT= CT target  CT reference)
[17].
3. Results and discussion
3.1. In silico prediction of sRNAs in P. acnes KPA171202
genome
Potential sRNA candidates were predicted using SIPHT [18].
SIPHT has an automatic workflow based on the intergenic
sequence conservation, presence of putative Rho-independent
terminators and several other features including primary
sequence conservation with previously annotated other regula-
tory RNAs. SIPHT has been widely used in sRNA prediction
studies in other micro organisms like Fransciella tularensis [28],
Streptococcus mutans [35], Burkholderia pseudomalle [14],
Mycobacterium smegmatis [32], and Brucella abortus [8]. The
complete genome of P. acnes KPA171202 was available at
NCBI for sRNA candidate prediction in SIPHT web interface.
A total of eight sRNAs candidates were predicted in P.
acnes KPA171202. Table 2 provides a detailed description of
the predicted sRNAs including genomic position, size, GC per-
centage, Blast expect value, upstream and downstream genes.
An additional file of results predicted by SIPHT explains this
in detail [see Supplementary data]. However some changes
have been made recently in Feb 2015 in the genome annotation
of some genes of P. acnes KPA171202 by Bruggemann and co-
workers (http://www.ncbi.nlm.nih.gov/nuccore/NC_006085.1)
which have been taken into consideration during presentation
of results.
3.2. Insilico validation
Sequences of the predicted sRNAs were analyzed using differ-
ent tools. The secondary structure predictions were carried out
using RNAfold program. Secondary structures based on the
lowest minimum folding energy are shown in Fig. 2, all sRNAs
were highly structured containing several stem loops similar to
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Figure 1 Growth curve of Propionibacterium acnes KPA171202.
Table 2 List of sRNAs predicted and their features. SIPHT (sRNA Identification Protocol using High-throughput Technologies)
predicted eight sRNA candidates.
sRNA
Name
Start/end
position
sRNA
length
GC
content (%)
Up GENE name Down GENE name BLAST
expect
sPPAK_1 951917–952181 264 57.2 Transposase Excinuclease ABC subunit A 2.20E07
sPPAK_2 2174934–2175009 75 61.3 Hypothetical protein GTP-binding protein TypeA 1.70E06
sPPAK_3 1372951–1372982 31 70.9 Sensory histidine kinase RNA polymerase sigma factor
RpoE
9.80E06
sPPAK_4 1583666–1583898 232 61.2 ATP-dependent DNA helicase
RecG
Ribonuclease 2.00E05
sPPAK_5 1719301–1719433 132 56.8 HNH endonuclease Hypothetical protein 1.00E05
sPPAK_6 1937987–1938035 48 81.25 Molecular chaperone GroES Hypothetical protein 1.00E05
sPPAK_7 2515653–2515851 198 65.6 Glycerol-3-phosphate
dehydrogenase
Hypothetical protein 0.0016
SRP_bact 252392–252480 88 67.04 RNA-binding protein S4 Hypothetical protein 9.70E06
172 P.P. Balgir et al.sRNAs validated in other bacteria [14]. Genomic location and
the orientations of sRNA, upstream and downstream genes
were also analyzed (Fig. 2). The sequence of sRNA genes
was analyzed for terminator prediction. Rho-independent ter-
minators were predicted at the 30 end using ARNold (Fig. 3).
Although, the study aimed to explore sRNAs in the intergenic
regions, one of the sRNA: sPPAK7 partially overlaps with the
protein coding gene. Recent annotation of the genome of
P. acnes KPA171202 shows that sPPAK4 completely lies
within the 50S ribosomal protein L28 encoding region. How-
ever, sPPAK4 sequence on translation using ExPasy translate
tool, did not yield any protein. Sequences of the predicted
sRNAs have start codons which are immediately followed by
stop codons. This indicates that these sRNAs are non-coding
in nature.
The candidate sRNAs were scanned against Rfam families
(version 10.1) to check the novelty of sRNAs. Out of eight
predicted sRNAs one showed homology in Rfam database
with a signal recognition particle and Rfam gave no significant
hits for other seven candidates indicating that these sRNAs are
novel bacterial sRNAs. Further experimental validation was
carried out for five sRNAs viz. sPPAK1, sPPAK2, sPPAK4,
sPPAK5 and sPPAK7.The genomic location of the sRNA sheds some light to
investigate the functions and targets of the sRNAs. The flank-
ing genes could be possible targets of these sRNAs. In the pre-
sent study, the upstream flanking genes of sPPAK4, sPPAK5
and sPPAK7 were found to be ATP-dependent DNA helicase
RecG, HNH endonuclease and Glycerol-3-phosphate
dehydrogenase respectively. All these genes show high
sequence complementarity and point to the cis regulatory
activity of respective sRNAs. Further investigations to prove
the same are underway.
3.3. Experimental validation of predicted sRNAs
Out of seven predicted sRNAs, experimentally five sRNAs
were tested and validated. Expression of the chosen sRNA
candidates was confirmed by RT-PCR. RNA was polyadeny-
lated and reverse transcribed to produce cDNA which was
amplified using primers designed specific for sPPAK1,
sPPAK2, sPPAK4, sPPAK5 and sPPAK7. The PCR products
visualized were 160, 59, 220, 132 and 194-bp bands confirming
the presence of sPPAK1, sPPAK2, sPPAK4, sPPAK5 and
sPPAK7 respectively among the sRNAs isolated from P. acnes
KPA171202. The same samples were electrophoresed on 3%
agarose gel and PCR products of exact predicted size were
obtained. Bands of sPPAK1, sPPAK4, sPPAK5 and sPPAK7
were excised from the gel and were purified for sequencing.
The sequencing results were consistent with the predictions
and the sequence of sPPAK1, sPPAK4, sPPAK5 and sPPAK7
was submitted to NCBI database with accession numbers
[Genbank: KF722796, KP881479, KP881480 and KP218043]
respectively.
3.4. Expression analysis by qPCR under different growth phases
It is well established that sRNA gene expression is growth
phase and stress related. The cellular abundance of each
validated sRNA was checked at different growth phases to
monitor their biosynthesis. The transcript level of all the
sRNAs, identified in this study was found to be most abundant
in stationary growth phase (Fig. 4). A number of sRNAs
of gram positive pathogens are growth phase dependent.
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Figure 2 Experimental detection, secondary structure and genomic orientation of five selected sRNAs of Propionibacterium acnes
KPA171202. (a) sPPAK1, (b) sPPAK2, (c) sPPAK4, (d) sPPAK5, (e) sPPAK7. The left column shows RT-PCR results of PCR amplicons
run on 15% PAGE with pUC19/Msp I digest as marker (Lane marked as ‘M’). The middle column displays secondary structures
predictions performed using RNAfold with lowest minimum folding energy. The right column shows genomic orientation of the validated
sRNAs. The gray arrow represents sRNA and white arrows are upstream and downstream genes; the direction of arrows shows orientation.
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sPPAK1- 264 nt
+1   5’-start
GCCTGGCCGCGGGCGGTCTGCAAGCTTGGCCGGGTCCTGACCAAGCGCGGCGAGGACATCCTCGCG
TTCTTACCACCACGGCTCCAGCAACGACCCCACCGAAGCGATCAACGGACGTCTCGAACACCTCCAC
GGCACCGCCCGCAGCTTTCAGACCCTCCTTACCCACGGCACCACCAGATCCCTCTTGGAAATCGGCA
GATCCAGACCCCAACAACACTCCCGAACCGTGAAAAGCCCGAAAACCTCTAGAGGGAAATAACTGT
CCTTTTCTCCGTCAATCACCACGGTGACGGGTATTTTCTTTACCCTAAAGCAGC
3’-end +264
sPPAK2- 75 nt
+1   5’-start
TGCAAACACACCACAGTGAAGTGTAGGTCAGGGCAGGGTTGCGCCACGAATGAGCGAGTCAGCGCC
ACCTTCAGGAGCGCGAATGTGGTGACTGGGCCGCAGTTTTCTCAGCAGTCGTGTGGGTTCC
3’-end +75
sPPAK4- 232 nt
+1   5’-start
GCGTCGGGTGCATCTTGCACCCGGCCCTGAACAGGAGATCTCCCAGTGGCTGCTGTGTGTGACATCT
GCGCTAAGCGCCCCGGTTTCGGACACAACGTCCCCTGGTCGAAGAAGAAGACCAATCGCCGGTGGA
GCCCGAACATTCAGCGCGTCCGTGTCGTCGAGAACGGCACGCATAAGCGCATGAACGTGTGCACTT
CGTGCCTCAAGGCTGGTCGAGTCAGCCGCTGAGCGCCGCGTTTGACGATGGAACCCGCCGTAAGGC
GGGTTCTTTGTCGTTATGGGTCGAT
3’-end +232
sPPAK5- 132 nt
+1   5’-start
GCCCGGCTGGCGTCGGCGCTGTATGGGCAGGCCGCGTGAACCTAGCCGCCAAAAGGTGTCAAGAAC
TGCGGATGCATTTAGGGTTTCGGGCCTGCAATGATGTAGGTGGTTGAAAAGTAGGAAAAGCCCCAG
GGCAAGCCCGGTCATCGGCTGGGTGCCTTGGGGCTTTGCCGTGTCCGGGAAAGGGG
3’-end +132
sPPAK7- 198 nt
+1   5’-start
CTGCAATCCTGAGCATCTTCGTACCTCCGAAGATGGGTTGAGGCCCGGCTGTGGGCCCGACGCAATT
CACGCTAGCCCTGGGCCGCGCGCGATTCCCACCTTCGTCGAGAGCCTGCACTTGCGTGCATGACGGC
TGCGGCTCCTCCTTCACCCAAGGGCGAGCTCCGCAACGCTGGCATCGACAACCAGGTCAGTACACAA
ACCACCGCGCAGGGCTACCCCCAGAGCCTCTGCTTTTTCGGCTCCGGATGCGAC
3’-end +198
Figure 3 Sequence analysis of validated sRNAs. The sequence shown in bold letters is sRNA sequence and unbold letters show
upstream and downstream sequences. The region highlighted in green and yellow shows start and stop codons respectively. The region
highlighted with gray color depicts putative rho independent terminator. 50 and 30 start and ending sites respectively are as predicted by
SIPHT.
Figure 4 qPCR detection the transcript levels of validated sRNAs under different growth phases. Statistical significance (*P 6 0.05;
**P 6 0.01) was obtained using Anova test.
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validated, many of them accumulated in the late-exponential
phase of growth and responded to acid stress [9]. Shioya and
co-workers [30] experimentally characterized 11 sRNAs in
Enterococcus faecalis V583 out of which, six sRNAs were
specifically expressed at exponential phase, two sRNAs were
observed in stationary phase, and three were detected during
both phases. Expression of twenty-four sRNA genes of Strep-
tococcus pyogenes M49, were also regulated in a growth phase
and/or medium dependent fashion [27]. In Clostridium difficile
expression of six sRNAs was growth phase dependent out of
which three sRNAs (RCd4, RCd5 and SQ1002) were induced
at the onset of stationary phase, whereas the expression of
three others (RCd2, RCd6 and SQ1498) was high during expo-
nential phase and decreased at the onset of stationary phase. It
was proposed that some of these growth phase regulated
sRNAs are involved in the control of virulence determinants
and associated factors which are also growth phase dependent
[31]. In the case of the present study, the five validated sRNAs
appear during both exponential and stationary phases of
growth but these are found to be maximally expressed during
stationary growth phase. These results provide a starting point
toward understanding of complex sRNA-based regulatory net-
work. Further transcriptome based investigations will help to
understand the molecular mechanism and biological pathways
regulated by these sRNAs.
4. Conclusions
This report presents the first study of small non-coding RNAs
reported so far on P. acnes KPA171202. Eight sRNAs were
predicted by SIPHT in P. acnes, out of which one showed
homology in Rfam database with a signal recognition particle.
Seven sRNAs thus were selected as putative regulatory mole-
cules. The experimental validation was carried out successfully
by RT-PCR for five sRNAs. These sRNAs were further ana-
lyzed and found to be maximally expressed under stationary
growth phases. Their growth phase dependence point to their
regulatory nature, with a probable role in pathogenesis, host
pathogen interaction, environmental stress coping mechanisms
and other physiological pathways. Further studies to gather
such information are being carried out. The unique nature of
sRNAs can be exploited for the development of novel diagnos-
tic tools and therapeutic interventions such as antisense PNAs
(peptide nucleic acids) as anti-bacterial drugs [24].Acknowledgements
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